President Joe Biden is directing HHS, through an executive order, to use the Innovation Center to lower drug prices; the US extended the COVID-19 public health emergency for another 90 days; the CDC reported that 75% of teenagers experienced adverse childhood experiences in 2021, which worsened their mental health.
The White House announced that President Joe Biden will sign an executive order directing HHS to explore new ways to lower prescription drug costs. Specifically, the order directs HHS to use the Innovation Center, which focuses on alternative payment models, to expand into drug pricing affordability. HHS will have 90 days to report its plans to lower drug prices. The president will sign the order during a trip to the West Coast Friday and Saturday as Medicare open enrollment season begins.
HHS Thursday extended the COVID-19 public health emergency for another 90 days. The declaration has been renewed every 90 days since it was first put into place in January 2020. White House officials are concerned about upcoming colder weather and fall and winter holidays, The Hill reported.
The CDC reported Thursday that most US adolescents had adverse childhood experiences (ACEs) during the pandemic, worsening their mental health. Physical abuse, emotional abuse, food insecurity, or loss of a parent’s job were exerienced by nearly 75% of teenagers last year, as well as electronic bullying, dating violence, and sexual violence. Data from the 2021 Adolescent Behaviors and Experiences Survey indicate that rates of poor current mental health and reporting a past-year suicide attempt among teens with 4 or more ACEs were 4 and 25 times as high as in those without ACEs, respectively.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More